Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
Completed · Phase 2
Conditions studied: Lymphoma
In brief
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving doxorubicin hydrochloride liposome and rituximab together with combination chemotherapy works in treating patients with newly diagnosed Burkitt's lymphoma or Burkitt-like lymphoma.
Key facts
- Study ID
- NCT00392990
- Run by
- Northwestern University
- People needed
- 25
- Starts
- 2007-02-06
- Expected to finish
- 2013-05-28
- Last updated by the study team
- 2019-10-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
- John H. Stroger Cook County Hospital — Chicago, Illinois, United States
- Rush University Medical Center — Chicago, Illinois, United States
- Loyola University Medical Center — Maywood, Illinois, United States
- Advocate Lutheran General Cancer Care Center — Park Ridge, Illinois, United States
- Washington University — St Louis, Missouri, United States
- The Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
- University Hospitals Case Medical Center — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.